Indications for a second prostate biopsy in patients suspected with prostate cancer after an initial negative prostate biopsy

Lee, Kwang Suk; Koo, Kyo Chul; Lee, Seung Hwan; Han, Woong Kyu; Choi, Young Deuk; Hong, Sung Joon; Park, Sang Un; Lee, Suk Young; Ko, Woo Jin; Kim, Young Sig; Chung, Byung Ha

doi:10.1016/j.prnil.2016.12.002

Cited by 2 publications

(2 citation statements)

References 21 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The PSAV and an increase in the PSA level have been reported as significant predictors of a positive repeat biopsy. 16 17 18 19 20 21 22 However, the definitions of these parameters were not consistent among the previous studies in terms of the regular interval for the monitoring of the PSA level. In the present study, the PSAVs calculated at 6-month intervals between the initial and repeat prostate biopsies were not predictors of prostate cancer among all patients and in the sub-groups.…”

Section: Discussionmentioning

confidence: 68%

Prostate-Specific Antigen Kinetics Following 5α-Reductase Inhibitor Treatment May Be a Useful Indicator for Repeat Prostate Biopsy

et al. 2018

Self Cite

View full text Add to dashboard Cite

PurposeTo evaluate parameters for determining repeat prostate biopsy in patients with 5α-reductase inhibitor (5ARI) treatment after initial negative biopsy.Materials and MethodsFrom January 2007 to December 2015, patients who underwent a repeat prostate biopsy after an initial negative biopsy were enrolled from multiple institutions. Serial prostate-specific antigen (PSA) levels after the initial biopsy were analyzed for PSA kinetics. Clinicopathologic variables were evaluated according to the use of 5ARIs after the initial negative biopsy.ResultsOf 419 patients with initial negative biopsies (median age=67.0 years, median PSA=6.31 ng/mL), 101 patients (24.1%) were diagnosed with prostate cancer at the repeat biopsy. An increase in PSA level at 18 months, compared to that at 6 months, was a predictor of a positive repeat biopsy. However, the use of 5ARIs was not identified as a predictor. Of 126 patients receiving 5ARI treatment after the initial biopsy, 30 (23.8%) were diagnosed with prostate cancer at the repeat biopsy. Increase in PSA level at more than two time points after 6 months of 5ARI treatment (odds ratio=4.84, p=0.005) was associated with cancer detection at the repeat biopsy. There were no significant 5ARI group-related differences in the detection rates of prostate and high-grade cancers (Gleason score ≥7).ConclusionThe effects of 5ARIs on prostate cancer detection and chemoprevention remain uncertain. However, more than two increases in PSA level after 6 months of 5ARI treatment may indicate the presence of prostate cancer.

show abstract

Section: Discussionmentioning

confidence: 68%

Prostate-Specific Antigen Kinetics Following 5α-Reductase Inhibitor Treatment May Be a Useful Indicator for Repeat Prostate Biopsy

et al. 2018

Self Cite

View full text Add to dashboard Cite

show abstract

“…However, the possibility of PCa should always be kept in mind, and these patients should be closely followed up with serial digital rectal examination and serum PSA measurements. Or, as such in recent years, the use of various imaging techniques such as contrast-enhanced ultrasound, sonoelastography, and multiparametric prostate magnetic resonance imaging (mpMRI) may be rationale [7][8][9].…”

Section: Discussionmentioning

confidence: 99%

Does serum prostate specific antigen levels correlate with the prostatic inflammation in elderly patients without clinically proven prostate cancer?

ÇOLAKEROL

TEMİZ

Boran

et al. 2022

The European Research Journal

View full text Add to dashboard Cite

Objectives: To determine the whether histological prostatic inflammation correlates with serum prostate specific antigen (PSA), free PSA (fPSA) and percent of fPSA (%fPSA) levels in elderly patients without clinically proven prostate cancer. Methods: A total of 115 patients without clinically proven prostate cancer with transrectal prostate biopsy were included in this retrospective study. Patients were divided two main groups as patients with and without histologic prostatic inflammation. A grading of the histological prostatic inflammation was performed and patients with prostatic inflammation were divided into three subgroups. The age, prostate volume, serum PSA, fPSA and %fPSA levels were compared between patients with and without prostatic inflammation. Correlation between the parameters and grade of prostatic inflammation was also investigated. Results: Serum PSA and %fPSA levels were significantly higher in men with histologically proven prostatic inflammation (15.47 ± 15.28 ng/mL vs. 11.67 ± 8.12 ng/mL; p = 0.002 and 19.8 ± 0.7 vs. 15.79 ± 0.9; p = 0.01, respectively). The mean serum PSA levels were significantly different among the subgroups (p = 0.02) and prostatic inflammation correlated positively with the PSA levels (r = 0.320, p < 0.001). Conclusions: Our findings suggested that reporting the grade of prostatic inflammation in elderly patients may help avoiding unnecessary repeat biopsies if elevated serum PSA level is the only indication for initial prostate biopsy.

show abstract

Indications for a second prostate biopsy in patients suspected with prostate cancer after an initial negative prostate biopsy

Cited by 2 publications

References 21 publications

Prostate-Specific Antigen Kinetics Following 5α-Reductase Inhibitor Treatment May Be a Useful Indicator for Repeat Prostate Biopsy

Prostate-Specific Antigen Kinetics Following 5α-Reductase Inhibitor Treatment May Be a Useful Indicator for Repeat Prostate Biopsy

Does serum prostate specific antigen levels correlate with the prostatic inflammation in elderly patients without clinically proven prostate cancer?

Contact Info

Product

Resources

About